

USSN 10/677,214

GTI-1110-CT

AMENDMENT - claims

Please amend the claims as follows:

1. (currently amended) A method for inhibiting cell growth or enhancing cell death comprising:
 - a) providing a photosensitive agent to a cell, wherein photosensitive agent is delivered as part of a pharmaceutically acceptable formulation that further comprises a pharmaceutically acceptable carrier and does not include liposomes;
 - b) applying an electric pulse to the cell of a sufficient strength and duration to electroporate the cell with the photosensitive agent; and
 - c) applying light of an activatable wavelength to the cell thereby activating the agent and inhibiting cell growth or enhancing cell death.
2. (currently amended) ~~The method of A method according to claim 1~~, wherein multiple pulses are applied to the cell.
3. (currently amended) ~~The method of A method according to claim 1~~, wherein the pulse amplitude is about 8410 kV/cm to about 6.0 kV/cm.
4. (currently amended) ~~The method of A method according to claim 1~~, wherein the pulse width is about 0.1 milliseconds to about 10 milliseconds.
5. (currently amended) ~~The method of A method according to claim 1~~, wherein the pulse is applied using at least two electrodes.
6. (currently amended) ~~The method of A method according to claim 5~~, wherein at least one light conductor is combined with the electrode.
- 7-9. (canceled)
10. (currently amended) ~~The method of A method according to claim 6~~, wherein the electrodes

USSN 10/677,214

GTI-1110-CT

comprise at least two needle electrodes.

11. (currently amended) The method of A method according to claim 10, wherein the needle electrodes are heatable.

12. (canceled)

13. (currently amended) The method of A method according to claim 1, wherein the light is applied prior to, simultaneously with, or following the pulse.

14. (currently amended) The method of A method according to claim 1, wherein the light is applied by a laser.

15. (currently amended) The method of A method according to claim 1, wherein the light is applied by a tungsten lamp.

16. (currently amended) The method of A method according to claim 1, wherein the light is applied by a near ultraviolet lamp.

17. (currently amended) The method of A method according to claim 1, wherein the light has a wavelength of about 300 nm to about 950 nm.

18. (currently amended) The method of A method according to claim 4, wherein the amount of light applied is about 50 J/cm² to about 1000 J/cm².

19. (currently amended) The method of A method according to claim 1, wherein the light is applied extracorporeally.

20-26. (canceled)

27. (currently amended) The method of A method according to claim 1, wherein the photosensitive agent is a cytostatic agent.

28. (currently amended) The method of A method according to claim 27, wherein the cytostatic agent is selected from the group consisting of daunomycin, adriamycin and actinomycin.

USSN 10/677,214

GTI-1110-CT

29. (canceled)

30. (currently amended) The method of A method according to claim 2927, wherein the photosensitive agent is 1 acetylneic acid.

31. (currently amended) The method of A method according to claim 30, wherein the photosensitive agent is protoporphyrin IX.

32. (currently amended) The method of A method according to claim 1, wherein the method is performed in a subject.

33. (currently amended) The method of A method according to claim 32, wherein the subject is a human.

34. (canceled)

35. (currently amended) The method of A method according to claim 1, wherein the electrodes comprise meander electrodes.

USSN 10/677,214

GTI-1110-CT

36. (currently amended) The method of A method according to claim 1, wherein said method is for treating a cell proliferative disorder by administering the photosensitive agent to a subject having or suspected of having a cell proliferative disorder.

37. (currently amended) The method of A method according to claim 36; wherein the cell proliferative disorder is benign.

38. (currently amended) The method of A method according to claim 36, wherein the cell proliferative disorder is a cancer.

39. (currently amended) The method of A method according to claim 38, wherein the cancer is selected from the group consisting of skin cancer, a solid tumor, a metastasizing cancer and hematopoietic cancer.

40. (currently amended) The method of A method according to claim 39, wherein the hematopoietic cancer is histiocytic lymphoma.

41. (currently amended) The method of A method according to claim 36, wherein multiple pulses are applied to the cell.

42-79. (canceled)